Related Experiment Videos
[Molybdocene dichloride as an antitumor agent (author's transl)]
Zeitschrift Fur Naturforschung. Section C, Biosciences
|December 1, 1979
Summary
Molybdocene dichloride demonstrates significant antitumor activity, completely inhibiting Ehrlich ascites tumors in mice for 30 days. This discovery highlights its potential as a novel anticancer agent, similar to other metallocene dichlorides.
Area of Science:
- Organometallic Chemistry
- Cancer Research
- Pharmacology
Context:
- Ehrlich ascites tumor model in CF1 mice is a standard for evaluating anticancer agents.
- Metallocene dichlorides of titanium (d0) and vanadium (d1) have shown prior antineoplastic properties.
- Molybdocene dichloride represents a d2 system within this class of compounds.
Purpose:
- To evaluate the antitumor efficacy of molybdocene dichloride.
- To compare the antineoplastic potential of molybdocene dichloride with related metallocene dichlorides.
- To establish molybdocene dichloride as a promising candidate for cancer therapy.
Summary:
- Molybdocene dichloride exhibited potent antitumor activity against Ehrlich ascites tumor.
- A dosage of 75-100 mg/kg administered 24 hours post-transplantation resulted in 100% tumor inhibition up to day 30.
- This marks the first d2 metallocene dichloride system to display significant anticancer properties.
Impact:
- Molybdocene dichloride shows promise as a novel therapeutic agent for cancer treatment.
- The findings expand the scope of metallocene dichlorides as a class of anticancer drugs.
- Further research into molybdocene dichloride's mechanism of action and clinical applications is warranted.